VISEN Pharmaceuticals (FRA:T06) Beginning Cash Position: €81.04 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:T06 VISEN Pharmaceuticals FRA:T06
7 GF Score
Price €2.06
! 5 Warning Signs
View Full Analysis

What is VISEN Pharmaceuticals Beginning Cash Position?

VISEN Pharmaceuticals FRA:T06 7 Beginning Cash Position is €81.04 Mil as of Jun. 2026. GuruFocus rates FRA:T06 with a GF Score™ of 7/100. The stock has 5 warning signs investors should review.

VISEN Pharmaceuticals's Beginning Cash Position for the quarter that ended in Jun. 2026 was €81.04 Mil.

VISEN Pharmaceuticals's quarterly Beginning Cash Position increased from Jun. 2025 (€24.58 Mil) to Dec. 2025 (€97.72 Mil) but then declined from Dec. 2025 (€97.72 Mil) to Jun. 2026 (€81.04 Mil).

VISEN Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2023 (€80.46 Mil) to Dec. 2024 (€45.62 Mil) and declined from Dec. 2024 (€45.62 Mil) to Dec. 2025 (€24.69 Mil).

VISEN Pharmaceuticals Beginning Cash Position Related Terms

VISEN Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for VISEN Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

VISEN Pharmaceuticals Beginning Cash Position Chart

VISEN Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
119.52 80.46 45.62 24.69

VISEN Pharmaceuticals Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Beginning Cash Position Get a 7-Day Free Trial 44.54 -0.02 24.58 97.72 81.04
FRA:T06
7GF Score
VISEN Pharmaceuticals FRA:T06
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

VISEN Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of €81.04 Mil mean?
VISEN Pharmaceuticals (FRA:T06) has a Beginning Cash Position of €81.04 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on VISEN Pharmaceuticals and its competitors.
Is VISEN Pharmaceuticals' Beginning Cash Position too high?
VISEN Pharmaceuticals' current Beginning Cash Position is €81.04 Mil. Overall, VISEN Pharmaceuticals has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does VISEN Pharmaceuticals' Beginning Cash Position compare to ZTS?
VISEN Pharmaceuticals' Beginning Cash Position of €81.04 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on VISEN Pharmaceuticals and its competitors. VISEN Pharmaceuticals's current Beginning Cash Position is €81.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VISEN Pharmaceuticals stock overvalued right now?
VISEN Pharmaceuticals (FRA:T06) has a current Beginning Cash Position of €81.04 Mil. The current Beginning Cash Position is €81.04 Mil. VISEN Pharmaceuticals' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For VISEN Pharmaceuticals (FRA:T06), the current Beginning Cash Position is €81.04 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

VISEN Pharmaceuticals Business Description

Other Exchanges 02561:Hong Kong
Address 69 Jiuzhang Road, Suite 3-108, Floor 3, Building B, Hengtai Lixiang Chuangxin Tower, Suzhou, CHN
VISEN Pharmaceuticals is a late-stage, near-commercialization biopharmaceutical company focused on providing treatments in selected endocrinology diseases in China. It has one Core Product and two other pipeline drug candidates. Its Core Product, lonapegsomatropin, is a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency (PGHD), a common short stature in patients aged under 18 caused by insufficient growth hormone. TransCon CNP (navepegritide), one of its key drug candidates, is a long-acting prodrug of c-type natriuretic peptide for the treatment of achondroplasia (ACH), a short-limbed dwarfism that results in severe skeletal complications and comorbidities.
7GF Score

Get the complete analysis for FRA:T06

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.06
Price